PMID- 24055043
OWN - NLM
STAT- MEDLINE
DCOM- 20140912
LR  - 20131203
IS  - 1879-0305 (Electronic)
IS  - 1359-6101 (Linking)
VI  - 24
IP  - 6
DP  - 2013 Dec
TI  - ALK1-Smad1/5 signaling pathway in fibrosis development: friend or foe?
PG  - 523-37
LID - S1359-6101(13)00077-4 [pii]
LID - 10.1016/j.cytogfr.2013.08.002 [doi]
AB  - Fibrosis is a common phenomenon associated with several pathologies, 
      characterized by an excessive extracellular matrix deposition that leads to a 
      progressive organ dysfunction. Thus fibrosis has a relevant role in chronic 
      diseases affecting the kidney, the liver, lung, skin (scleroderma) and joints 
      (arthritis), among others. The pathogenesis of fibrosis in different organs share 
      numerous similarities, being one of them the presence of activated fibroblasts, 
      denominated myofibroblast, which act as the main source of extracellular matrix 
      proteins. Transforming growth factor beta-1 (TGF-beta1) is a profibrotic cytokine 
      that plays a pivotal role in fibrosis. The TGF-beta1/ALK5/Smad3 signaling pathway 
      has been studied in fibrosis extensively. However, an increasing number of 
      studies involving the ALK1/Smad1 pathway in the fibrotic process exist. In this 
      review we offer a perspective of the function of ALK1/Smad1 pathway in renal 
      fibrosis, liver fibrosis, scleroderma and osteoarthritis, suggesting this pathway 
      as a powerful therapeutical target. We also propose several strategies to 
      modulate the activity of this pathway and its consequences in the fibrotic 
      process.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
FAU - Munoz-Felix, Jose M
AU  - Munoz-Felix JM
AD  - Renal and Cardiovascular Research Unit, Department of Physiology and 
      Pharmacology, University of Salamanca, 37007 Salamanca, Spain; Biomedical 
      Research Institute of Salamanca (IBSAL), 37007 Salamanca, Spain; Institute Queen 
      Sophie for Renal Research, 37007 Salamanca, Spain.
FAU - Gonzalez-Nunez, Maria
AU  - Gonzalez-Nunez M
FAU - Lopez-Novoa, Jose M
AU  - Lopez-Novoa JM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20130913
PL  - England
TA  - Cytokine Growth Factor Rev
JT  - Cytokine & growth factor reviews
JID - 9612306
RN  - 0 (Extracellular Matrix Proteins)
RN  - 0 (Smad1 Protein)
RN  - 0 (Smad5 Protein)
RN  - 0 (Transforming Growth Factor beta)
RN  - EC 2.7.11.30 (ACVRL1 protein, human)
RN  - EC 2.7.11.30 (Activin Receptors, Type II)
SB  - IM
MH  - Activin Receptors, Type II/*metabolism
MH  - Animals
MH  - Extracellular Matrix Proteins/metabolism
MH  - Fibrosis/drug therapy/*metabolism
MH  - Humans
MH  - Smad1 Protein/*metabolism
MH  - Smad5 Protein/*metabolism
MH  - Transforming Growth Factor beta/metabolism
OTO - NOTNLM
OT  - Cirrhosis
OT  - Collagen
OT  - Extracellular matrix
OT  - Fibrosis
OT  - Smad
EDAT- 2013/09/24 06:00
MHDA- 2014/09/13 06:00
CRDT- 2013/09/24 06:00
PHST- 2013/07/26 00:00 [received]
PHST- 2013/08/14 00:00 [accepted]
PHST- 2013/09/24 06:00 [entrez]
PHST- 2013/09/24 06:00 [pubmed]
PHST- 2014/09/13 06:00 [medline]
AID - S1359-6101(13)00077-4 [pii]
AID - 10.1016/j.cytogfr.2013.08.002 [doi]
PST - ppublish
SO  - Cytokine Growth Factor Rev. 2013 Dec;24(6):523-37. doi: 
      10.1016/j.cytogfr.2013.08.002. Epub 2013 Sep 13.